Controversial Monologue On Steve Jobs Coming To NYC’s Public Theater

NEW YORK (1010 WINS) — The creator of the one man show The Agony and the Ecstasy of Steve Jobs, says it will go on as scheduled despite the Apple’s co-founder’s death.

LISTEN: 1010 WINS’ Glenn Schuck reports

Mike Daisey is taking his controversial monologue to New York’s Public Theater starting Tuesday.

The show is sharply critical. Daisey portrays Jobs as a control freak who utilized child labor in Chinese factories to advance Apple and insists he won’t tone down the show because Jobs has passed away.

“The show will transform immensely. If anything, it makes the need to examine the legacy that we’ve inherited from Jobs and that is now our responsibility, more important than ever” said Daisey. “So no, no softening at all.”

Calling Jobs a “genius of design and capitalism who was much beloved,” Daisey says Apple’s devices “were made by children under horrendous conditions.”

Daisey says he’s prepared for any public backlash because of his show.

The Agony and the Ecstasy of Steve Jobs runs from Oct. 11 to Nov. 13 at the Public Theater. For more information, click here.

What do you think? Sound off below in our comments section…


One Comment

  1. DaMag says:

    Steve Jobs was innovative, but in typical CNN fashion, they decide one view they are going to show and skip all the rest. Besides everything listed above, Jobs was also one of the main opponent to the ‘open source’ approach to computing. If Apple is anything, it is totally proprietary.

  2. DanTe says:

    What do you call a man who got his girlfriend pregnant and left her to rot with the child on welfare?

    What do you call a man who got paid $5,000 for a job and got his best friend to do all the work for a measly $350?

    What do you call a man who got an organ transplant within weeks while others die on a waiting list?

    You call this “man” Steve Jobs. A typical Apple user profile.

Comments are closed.

More From CBS New York

Get Our Morning Briefs

Watch & Listen LIVE